SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-02-12
Accession Number: 0001493152-26-006407
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226006407/forms-1.htm

Chunk 21 of 83
Word Count: 1474
Character Count: 9663

Document Content:

to adequately protect our proprietary technology or obtain and maintain issued patents that are sufficient to protect our product candidates, product candidates, and methods others could compete against us more directly, which could harm our business, financial condition and results of operations. Our intellectual property and proprietary rights are important to our ability to remain competitive and for the success of our product candidates and our business. Patent protection can be limited and not all intellectual property is or can be patented. Our commercial success may depend in part on our ability to obtain and maintain patents and other intellectual property rights in the United States and elsewhere, and protect our proprietary technologies. If we do not adequately protect our intellectual property and proprietary technologies, competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business and profitability.

have filed patent applications for our product candidates and related intellectual property with the U.S. Patent and Trademark Office
and in other jurisdictions. As of September 1, 2025, we have been granted over one hundred (100) patents including over 50 patents
in the United States, and we have another 7 pending applications in various stages of review.

Our
patents may not have, or our pending patent applications that mature into issued patents may not include, claims with a scope sufficient
to protect our product candidates, product candidates, or methods. Other parties may have developed technologies that may be related
or competitive to our product candidates, product candidates, and methods, may have filed or may file patent applications for those technologies,
and may have received or may receive patents that overlap or conflict with our patents or patent applications, either by claiming the
same product candidates or methods or by claiming subject matter that could dominate our patent position. The patentability of devices
and methods in our technical field may involve complex legal and factual questions, and, therefore, the scope, validity and enforceability
of any patent claims that we may obtain cannot be predicted with certainty.

Though
an issued patent is presumed valid and enforceable, its issuance is not conclusive as to its validity or its enforceability. Patents
may be challenged, deemed unenforceable, invalidated, circumvented, or found not infringed. Proceedings challenging our patents could
result in either the loss or reduction in scope of one or more of the claims of the patent. Furthermore, an adverse decision in an interference
proceeding or a derivation proceeding could result in a third party receiving the patent rights sought by us, which in turn could affect
our ability to commercialize our technologies. Any successful challenge to our patents could deprive us of exclusive rights necessary
for the successful commercialization of our product candidates and methods. In addition, defending such challenges may be costly.

Patents
have a limited lifespan. In the United States, the natural expiration of a utility patent is generally 20 years after its effective filing
date and the natural expiration of a design patent is generally 14 years after its issue date, unless the filing date occurred on or
after May 13, 2015, in which case the natural expiration of a design patent is generally 15 years after its issue date. Further, if we
encounter delays in our development efforts, the period of time during which we could market our product candidates and methods under
patent protection would be reduced and, given the amount of time required for the development, testing and regulatory review of planned
or future product candidates and methods, patents protecting such product candidates and methods might expire before or shortly after
such product candidates and methods are commercialized. As a result, our intellectual property may not provide us with sufficient rights
to exclude others from commercializing product candidates and methods similar or identical to ours.

Furthermore,
patents may not provide us with adequate proprietary protection or competitive advantages against competitors with similar product candidates.
Competitors may be able to design around our patents. Other parties may develop and obtain patent protection for more effective technologies,
designs or methods. The laws of some foreign countries do not protect our proprietary rights to the same extent as the laws of the United
States, and we may encounter significant problems in protecting our proprietary rights in these countries. Competitors may export otherwise
infringing product candidates to territories where we have patent protection but enforcement is not as strong as that in the United States.
These product candidates may compete with our product candidates, and our patents or other intellectual property rights may not be effective
or sufficient to prevent them from competing. If any of these developments were to occur, they each could have a negative impact on our
business and competitive position.

Our
ability to enforce our patent rights depends on our ability to detect infringement. It may be difficult to detect infringers who do not
advertise the use of infringing product candidates, the practice of infringing methods, or the incorporation of infringing components
in their product candidates. It may be difficult or impossible to obtain evidence of infringement in a competitor’s or potential
competitor’s product, or infringing uses or sales by a customer of a competitor. We may not prevail in any lawsuits that we initiate,
and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. In addition, third parties may attempt
to commercialize competitive product candidates or methods in foreign countries where we do not have any patents or patent applications
and/or where legal recourse may be limited. This may have a significant commercial impact on our foreign business operations.

addition, proceedings to enforce or defend our patents could put our patents at risk of being invalidated, held unenforceable or interpreted
narrowly. Such proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in
one or more of our patents are invalid or otherwise unenforceable. If any of our patents covering our product candidates, product candidates,
or methods are invalidated or found unenforceable, our financial position and results of operations could be negatively impacted. In
addition, if a court finds that valid, enforceable patents held by third parties cover one or more of our product candidates, product
candidates, or methods, our financial position and results of operations could be harmed.

rely upon unpatented trade secrets, unpatented know-how and continuing technological innovation to develop and maintain our competitive
position, which we may seek to protect, in part, by entering into confidentiality agreements with our employees, suppliers, vendors,
collaborators, and/or consultants. We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or trade
secrets by consultants, suppliers, vendors, former employees and current employees. If parties to any such agreements breach or violate
the terms of any such agreements, we may not have adequate remedies for the breach or violation, and we could lose our trade secrets
through the breach or violation. Also, it is possible that technology relevant to our business will be independently developed by a person
that is not a party to such an agreement. Further, our trade secrets could otherwise become known or be independently discovered by our
competitors, which could diminish the value and competitive worth of those trade secrets.

we fail to comply with our obligations in the agreements under which we may license intellectual property rights from third parties or
otherwise experience disruptions to our business relationships with our licensors, we could lose rights that are important to our business.

have licensed and may enter into or may be required to enter into intellectual property license agreements that are important to our
business. These license agreements may impose various diligence, milestone, payment, royalty and other obligations on us. For example,
we may enter into exclusive license agreements with various universities and research institutions, we may be required to use commercially
reasonable efforts to engage in various development and commercialization activities with respect to licensed product candidates, and
may need to satisfy specified milestone and royalty payment obligations. If we fail to comply with any obligations under our agreements
with any of these licensors, we may be subject to termination of the license agreement in whole or in part, increased financial obligations
to our licensors or loss of exclusivity in a particular field or territory, in which case our ability to develop or commercialize product
candidates covered by the license agreement will be impaired.

addition, disputes may arise regarding intellectual property subject to a license agreement, including:

●	the
scope of rights granted under the license agreement and other interpretation-related issues;

●	the
extent to which our processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;

●	our
diligence obligations under the license agreement and what activities satisfy those obligations;